<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00635284</url>
  </required_header>
  <id_info>
    <org_study_id>CA401</org_study_id>
    <nct_id>NCT00635284</nct_id>
    <nct_alias>NCT00573677</nct_alias>
  </id_info>
  <brief_title>ABI-009 Trial in Patients With Advanced Non-hematologic Malignancies</brief_title>
  <official_title>A Phase I Trial of ABI-009 (Nab-rapamycin) Administered Weekly in Patients With Advanced Non-hematologic Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009&#xD;
      given weekly; to characterize the toxicities of ABI-009; and to determine the pharmacokinetic&#xD;
      parameters for ABI-009 when given on a weekly schedule.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      No extended description necessary&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2007</start_date>
  <completion_date type="Actual">June 1, 2011</completion_date>
  <primary_completion_date type="Actual">June 1, 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) of ABI-009 administered weekly and pharmacokinetic parameters for ABI-009.</measure>
    <time_frame>End of Study (EOS) and Follow Up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ABI-009 in this patient population</measure>
    <time_frame>End of Study (EOS) and Follow Up</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Solid Tumors</condition>
  <arm_group>
    <arm_group_label>ABI-009</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ABI-009</intervention_name>
    <description>nab-rapamycin</description>
    <arm_group_label>ABI-009</arm_group_label>
    <other_name>nab-rapamycin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Each subject must meet the following criteria to be enrolled in this study.&#xD;
&#xD;
          1. Male and female patients with histologically or cytologically confirmed diagnosis of&#xD;
             cancer which is not amenable to curative therapy.&#xD;
&#xD;
          2. Patients with advanced non-hematologic malignancies for whom no standard therapy&#xD;
             exists.&#xD;
&#xD;
          3. Measurable disease by RECIST or evaluable disease (e.g., bone metastasis, pleural&#xD;
             effusion, ascites, or lesions which do not fulfill RECIST criteria for metastatic&#xD;
             disease)&#xD;
&#xD;
          4. Off all therapy (inclusive of investigational therapies) for at least 4 weeks prior to&#xD;
             study drug administration OR off all daily or weekly therapy (inclusive of&#xD;
             investigational therapies) for at least 2 weeks prior to study drug administration and&#xD;
             without any side effects associated with these therapies.&#xD;
&#xD;
          5. Female patients of child-bearing potential must have a negative serum pregnancy test&#xD;
             within 7 days prior to first study drug administration.&#xD;
&#xD;
          6. Female patients who are postmenopausal must have 12 months of amenorrhea, surgically&#xD;
             sterile, or must agree to the use of a physical method of non-hormonal contraception.&#xD;
&#xD;
          7. Male patients must be surgically sterile or agree to the use of a barrier method of&#xD;
             contraception.&#xD;
&#xD;
          8. Life expectancy of &gt; 3 months.&#xD;
&#xD;
          9. ECOG Performance Status of 0-1.&#xD;
&#xD;
         10. Patients must be able to provide informed consent indicating knowledge of his/her&#xD;
             disease process, the investigational nature of the therapy, alternatives, benefits,&#xD;
             and risks including potential side effects.&#xD;
&#xD;
         11. Age ≥ 18 years of age.&#xD;
&#xD;
         12. No major surgery within 4 weeks before treatment with ABI-009. (A biopsy is not&#xD;
             considered major surgery).&#xD;
&#xD;
         13. No chemotherapy, hormonal therapy, immunotherapy or radiotherapy within 4 weeks before&#xD;
             treatment with ABI-009 (6 weeks for previous treatment with nitrosoureas, mitomycin,&#xD;
             or extensive radiotherapy) and no immunosuppressive agents within 3 weeks before study&#xD;
             entry (except corticosteroids used as antiemetics).&#xD;
&#xD;
         14. No immunosuppressive agents within 3 weeks before study entry (except corticosteroids&#xD;
             used as antiemetics).&#xD;
&#xD;
         15. Required Initial Laboratory Data:&#xD;
&#xD;
               -  Hemoglobin &gt; 9.0 g/dL&#xD;
&#xD;
               -  WBC ≥ 3,000/µl&#xD;
&#xD;
               -  ANC ≥ 1,500/µl&#xD;
&#xD;
               -  Platelet count ≥ 100,000/µl&#xD;
&#xD;
               -  Total Bilirubin ≤ ULN&#xD;
&#xD;
               -  SGOT (AST) SGPT (ALT) ≤ 1.5 x ULN ≤ 1.5 x ULN&#xD;
&#xD;
               -  Serum Cholesterol &lt; 350 mg/dL&#xD;
&#xD;
               -  Serum Triglyceride &lt; 300 mg/dL&#xD;
&#xD;
         16. Adequate renal function with serum creatinine &lt; 1.5 mg/dL and/or creatinine clearance&#xD;
             (cockroft formula) ≥ 60 mL/min.&#xD;
&#xD;
         17. No active alcohol abuse, drug addiction, or psychotic disorders.&#xD;
&#xD;
         18. No known concomitant genetic or acquired immunosuppressive diseases (such as AIDS).&#xD;
&#xD;
         19. If obese, a patient must be treated with doses calculated using his/her actual BSA&#xD;
             (The physician must be comfortable treating at the full BSA dose regardless of BSA).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria will be excluded from the study.&#xD;
&#xD;
          1. Pregnant or nursing women.&#xD;
&#xD;
          2. History of allergic reactions attributed to compounds of similar chemical or biologic&#xD;
             composition including macrolide (e.g. azithromycin, clarithromycin, dirithromycin, and&#xD;
             erythromycin) and ketolide antibiotics.&#xD;
&#xD;
          3. Patients have not recovered from adverse affects of radiation therapy or&#xD;
             investigational agent within previous 28 days.&#xD;
&#xD;
          4. Uncontrolled intercurrent illness that in the opinion of the investigator would limit&#xD;
             compliance and tolerance to study requirements&#xD;
&#xD;
          5. Patients with known brain metastases or leptomeningeal tumor involvement.&#xD;
&#xD;
          6. Receiving any of the following: concomitant antitumor therapy or inhibitors of CYP3A4.&#xD;
&#xD;
          7. Patients with history of interstitial lung disease and/or pneumonitis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ana M. Gonzalez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sant P. Chawla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sarcoma Oncology Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sarcoma Oncology Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas M.D. Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin Cancer Res. 2013 Oct 1;19(19):5474-84. doi: 10.1158/1078-0432.CCR-12-3110.</citation>
    <PMID>24089446</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>March 7, 2008</study_first_submitted>
  <study_first_submitted_qc>March 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 13, 2008</study_first_posted>
  <last_update_submitted>October 16, 2019</last_update_submitted>
  <last_update_submitted_qc>October 16, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

